V

Vanda Pharmaceuticals
D

VNDA

4.32000
USD
0.08
(1.89%)
مغلق
حجم التداول
9,923
الربح لكل سهم
-1
العائد الربحي
-
P/E
-6
حجم السوق
254,596,962
أصول ذات صلة
A
ALKS
-0.700
(-2.33%)
29.340 USD
AMGN
AMGN
-0.04
(-0.01%)
271.89 USD
BIIB
BIIB
-0.465
(-0.37%)
125.825 USD
BMRN
BMRN
-0.490
(-0.85%)
57.500 USD
GILD
GILD
0.670
(0.63%)
107.390 USD
INCY
INCY
-0.250
(-0.39%)
64.250 USD
REGN
REGN
-8.04
(-1.35%)
588.61 USD
المزيد
الأخبار المقالات

العنوان: Vanda Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.